Viatris Inc.
VTRS Healthcare Drug Manufacturers Specialty & Generic
Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024. In the quarter to June 2026, revenue grew 4.88%, EPS fell 2,464.1%, free cash flow grew 101.1% and total debt fell 18.1%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for five consecutive years.
Follow VTRS
Viatris Inc. (VTRS) Return on invested capital
Viatris Inc.'s return on invested capital over the twelve months to 30 June 2026 was −0.20%, up 5.4 percentage points from fiscal 2025 (−5.58%). Over the past ten years it has ranged from −5.58% (fiscal 2025) to 5.74% (fiscal 2015) — the current reading is the lowest in ten years. That is below the Drug Manufacturers Specialty & Generic industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −5.58% | (5.60) |
| FY2024 | 0.02% | (1.25) |
| FY2023 | 1.27% | (1.31) |
| FY2022 | 2.58% | 2.63 |
| FY2021 | −0.05% | 0.21 |
| FY2020 | −0.26% | (2.04) |
| FY2019 | 1.78% | (0.43) |
| FY2018 | 2.21% | (0.89) |
| FY2017 | 3.10% | 1.48 |
| FY2016 | 1.62% | (4.12) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| UTHR United Therapeutics Corporation compare | 23.4% |
| ZTS Zoetis Inc. compare | 19.6% |
| NBIX Neurocrine Biosciences, Inc. compare | 15.0% |
| RDY Dr. Reddy's Laboratories Ltd compare | 5.89% |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 4.58% |
| TAK Takeda Pharmaceutical Co. compare | 2.88% |
| ELAN Elanco Animal Health Incorporated compare | 0.51% |
| HLN Haleon PLC Sponsored ADR compare | 0.00% |
| VTRS Viatris Inc. | −0.20% |
| Drug Manufacturers Specialty & Generic industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on VTRS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement